You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆指午後升幅收窄 醫藥股普遍反彈
恆指今早反覆回升319點至15,805(受制20天線),午後在權重金融分類指數倒跌拖累,升幅明顯收窄至僅77點或0.5%,現報15,562,總成交額694億元。 醫藥股今天普遍隨大市反彈,尤其是榮昌生物(09995.HK)扭五連跌,股價由早段所創上市低位15.06元回升,最高見17.2元,現報16.96元,升11%。金斯瑞(001548.HK)由早段近三年低位12.64元,回升高見14.14元,現報13.78元,升6.3%。 去年11月中旬才以每股20.6元上市的藥明合聯(02268.HK)預告去年多賺逾80%,大摩料該股未來30天有七八成概率上升,給予「增持」評級看40.6元。藥明合聯扭五連跌,現報21元,回升5.5%。藍籌藥明生物(02269.HK)及藥明康德(02359.HK)也由低位止跌回升,最高見21.85元及56.8元,現報20.9元及55.5元,反彈2%及2.8%。 藍籌翰森(03692.HK)、石藥(01093.HK)、中生(01177.HK)、康希諾生物(06185.HK)、康寧傑瑞製藥-B(09966.HK)、雲頂新耀-B(01952.HK)、再鼎醫藥(09688.HK)、艾美疫苗(06660.HK)、聯邦制藥(03933.HK)、信達生物(01801.HK)、歌禮製藥-B(01672.HK)及康方生物(09926.HK)升近2%-5%,後者最強,現報41.55元,回升4.8%重越10天線(41.4元)。泰凌醫藥(01011.HK)由回升26%報4.3仙。 凱萊英(06821.HK)擬使用自有資金最多12億人民幣回購A股,每股價格最高157元人民幣,H股扭四連跌,現報64元,回升5.5%;凱萊英A(002821.SZ)也回升6.4%,現報91元人民幣。(sz/u) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account